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A hallmark of human tumors is the loss of p53 or its 
transcriptional functions. In this study, we describe the 
generation of the conditionally replicating adenovirus 
Adp53sensor for the treatment of p53-dysfunctional 
tumors. p53-selective attenuation of viral replication 
was achieved by using p53-dependent expression of the 
transcriptional repressor Gal4-KRAB that was directed 
against the adenoviral E1A locus. Adp53sensor shows 
efficient replication in p53-dysfunctional, but not in p53-
active cells. In p53-dysfunctional cells, p53-analogous 
transcriptional activity by other p53 family members was 
not sufficient to compromise replication of Adp53sen-
sor. In comparison with a genetically similar, but p53-
insensitive virus, Adp53sensor replication was inhibited 
after systemic infection of p53-wt-mice, but not in p53-
ko-mice thus confirming the correct function of the cho-
sen approach. Adp53sensor showed efficient lytic and 
replicative properties in all investigated cells with p53-
dysfunction and successfully inhibited the growth of 
subcutaneous xenotransplants in vivo. We further dem-
onstrated that intravenous injection of Adp53sensor lead 
to significantly reduced liver damage compared to the 
control virus. Together, our data show that Adp53sen-
sor is an oncolytic, p53-selective adenovirus for efficient 
treatment of p53-dysfunctional tumors with a favorable 
toxicity profile. Moreover, Adp53sensor provides a strat-
egy that should be applicable to other transcriptionally 
regulated DNA viruses.
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IntroductIon
Tumor selectively replicating oncolytic viruses are a novel class of 
antineoplastic agents that hold promise to overcome limitations 
of conventional cancer therapy. For the generation of oncolytic 
viruses, tumor-specific promoters have been used to control E1A 
expression and viral replication. However, this approach is often 
limited by weak promoter activity and heterogeneous activity in 
different tumor subzones. Additionally, E1A accumulation due to 
basal promoter activity in normal cells can finally lead to replica-
tion onset and loss of selectivity, in particular at high multiplicities 
of infection.1,2 Consequently, alternative strategies are required 
that ensure stringent regulation of viral replication in response to 
crucial oncogenic pathway aberrations.
The tumor suppressor p53, which normally controls genomic 
stability and cell cycle control, is genetically or epigenetically 
altered in the majority of human tumors. p53-activity is induced 
following diverse genotoxic stimuli and results in transcriptional 
activation of proapoptotic genes, cell cycle arrest, and apoptosis.3,4 
Because alterations of the p53-pathway leading to a loss of p53-
transcriptional functions are fundamental events in carcinogen-
esis, p53-transcriptional deficiency represents an ideal target for 
tumor therapy.
Therefore, p53-selective virotherapy has been addressed 
first by the use of the oncolytic adenovirus dl1520 (Onyx-015), 
an E1B-55k mutant originally designed to replicate specifi-
cally in p53-dysfunctional cells. However, E1B-55k is not only 
an important inhibitor of p53 but also exerts further important 
and versatile functions that support the viral replication cycle.5–7 
Furthermore, the adenoviral E4orf1 has been shown to limit the 
oncolytic potential of E1B-55k-deleted oncolytic adenoviruses.8 
Consequently, the replication of Onyx-015 is often severely com-
promised in p53-dysfunctional cancer cells and first experiences 
of clinical applications did not meet high expectations. To circum-
vent manipulations of key viral proteins such as E1B-55k, and to 
maintain the natural replication cycle of the virus, we constructed 
a p53-dependent oncolytic adenovirus without any alterations of 
early viral gene products. Tumor selectivity of this virus, desig-
nated Adp53sensor, is achieved by chemotherapy-triggered, p53-
dependent expression of the transcriptional repressor Gal4-KRAB, 
which in turn inhibits the expression of the early viral E1A gene. 
Our results show that Adp53sensor replication and oncolysis are 
restricted to p53-dysfunctional cells and is not compromised by 
endogenous activity of other members of the p53 family that can 
potentially compensate the loss of p53-transcriptional functions. 
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Adp53sensor showed improved replication kinetics and oncolysis 
in tumor cells, and enhanced tumor selectivity in vitro and in vivo 
compared to Onyx-015. Furthermore, Adp53sensor exhibited sig-
nificantly increased therapeutic efficacy. In combination with che-
motherapy, Adp53sensor efficiently inhibited growth of aggressive 
human tumor xenografts in vivo.
results
cell stress mediated by chemotherapy and/
or adenoviral infection induce expression of 
p53: a stress-induced pathway that facilitates 
chemotherapy-assisted, p53-dependent virotherapy
High adenovirus load or doxorubicin chemotherapy can trig-
ger DNA damage pathways and subsequent activation of p53 in 
vivo.9,10 To investigate the intracellular p53-response after viral 
transduction, we treated p53-wt cells with a replication-incompe-
tent adenovirus and/or doxorubicin. Both treatments were applied 
at low dose to reflect a physiologic environment for a p53-selective 
oncolytic adenovirus. Application of single agents led to upregula-
tion of p53 in a dose-dependent manner and combined treatment 
further increased p53 levels (Figure 1a,b). We could recently 
demonstrate that chemotherapy does not compromise adenovi-
ral replication and leads to improved oncolysis.11 Therefore, our 
results suggest that chemotherapy-assisted adenoviral infection 
sufficiently triggers an intracellular p53-response that could be 
exploited to regulate conditional adenoviral replication in a p53-
dependent manner. Consequently, we developed a vector concept 
(termed Adp53sensor, Figure 1c,d) harboring a p53-sensitive pro-
moter for p53-restricted expression of the transcriptional repressor 
Gal4-KRAB. The repressor in turn binds to the cytomegalovirus 
(CMV)-promoter variant CMVgal and silences transcription of 
E1A. CMVgal consists of a 474 base-pair long CMV-promoter 
sequence equipped with internal and flanking clusters of Gal4-
binding sites to attract Gal4-KRAB as described previously.12 This 
genetic setup allows for inhibition of E1A expression under non-
permissive conditions and for high E1A levels under permissive 
conditions (Figure 1e). The CMVgal-promoter shows a higher 
transcriptional activity compared to the wild-type E1A-promoter, 
but is susceptible for efficient transcriptional repression by Gal4-
KRAB (Figure 1f).
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Figure 1 p53 activation upon adenoviral cell entry and chemotherapy provides the basis for the construction of Adp53sensor. (a) HepG2 and 
A549 were treated with indicated MOIs/doses of Ad-LacZ or doxorubicin, or (b) with combinations of both agents (MOI 50; 200 ng/ml). Western blot 
analyses revealed that p53 was induced by adenoviral infection and/or doxorubicin in a dose-dependent manner. (c) Strategy for selective adenovi-
ral replication in p53-transcriptional-deficient cells. The bicistronic adenovirus Adp53sensor contains a p53-dependent promoter for control of the 
Gal4-KRAB repressor, functioning here as sensor element for the p53-transcriptional activity of the target cell. The second cistron contains the E1A 
gene under control of a GAL4-binding CMV-promoter mutant that can be silenced in the presence of Gal4-KRAB. (d) Illustration showing the genetic 
construction included in Adp53sensor and the p53-insensitive counterpart AdCtrl. (e) Illustration showing the genetic modifications included in the 
CMVgal-promoter to achieve efficient binding of Gal4-KRAB. (f) One microgram of the plasmids CMVwt-Luc, CMVgal-Luc, or prE1A-Luc were trans-
fected into HepG2 cells to determine promoter activity by luciferase assays. Half a microgram of prMinRGC-GAL4KRAB was co-transfected for p53-
dependent expression of the repressor, and doxorubicin was administered at a final concentration of 200 ng/ml. The data show that the promoter 
mutant CMVgal can be efficiently repressed by chemotherapy-triggered, p53-dependent expression of Gal4-KRAB. Ctrl, control; Doxo, doxorubicin; 
MOI, multiplicity of infection; RLU, relative light units; Luc, luciferase. **P < 0.005.
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the p53-dependent promoter prMinrGc is not 
transactivated by other members of the p53 family 
upon chemotherapy and adenoviral infection 
in cancer cells
To find a suitable p53-responsive promoter for application in 
Adp53sensor, we evaluated two artificial promoters, prMinCon 
and prMinRGC, that contain a CMV-minimal-promoter and 
either clusters of consensus or ribosomal gene cluster (RGC) 
sites for binding of p53. Both promoters can be strongly transac-
tivated by overexpressed p53 (Figure 2a). However, the prMin-
RGC-promoter provided a favorable activation/background 
ratio and was therefore selected for inclusion in Adp53sensor. 
In contrast to p53, other members of the p53 family are rarely 
altered in cancer, but several isoforms of p63 and p73 (collectively 
termed TAp63 or TAp73, respectively) can recognize p53-DNA-
binding sites and transactivate p53 target genes.13,14 Because it 
has been reported that TAp73 or TAp63 can be upregulated 
by chemotherapy or adenoviral infection,15–19 we investigated 
transactivation of p53-responsive promoters by overexpressed 
TAp63, TAp73α, and TAp73β (Figure 2a). Transactivation by 
TAp73β was comparable to p53, but TAp63 and TAp73β led 
only to low promoter activity. Because this responsiveness to 
TAp73β could potentially compromise a broad applicability of 
Adp53sensor, we investigated for prMinRGC-promoter acti-
vation in the context of endogenous levels of p53- and p53-
 homologues in a panel of cell lines (Figure 2b). The promoter 
was strongly activated in p53-wt cells, in particular in HepG2 
and A549. In p53-wt cells with epigenetic inhibition of p53 (such 
as 293 or HeLa), reporter expression was significantly reduced 
or almost completely abolished (A673). We could not find any 
cell line with genetic p53-dysfunction that showed a significant 
reporter activation including those with intact p73 (Figure 2c). 
This observation was unexpected because at least H1299 and 
SAOS-2 cells have been reported to upregulate p73 upon geno-
toxic stress.20,21 Analysis of nuclear TAp73 levels in these cells 
after stimulation confirmed the accumulation of TAp73β and/or 
TAp73α (Figure 2d), though the observed protein levels seemed 
to be rather low. Consistently, it has been reported that p73 iso-
forms are expressed at lower level than uninduced p53, even 
after chemotherapeutic stimulation.22 In contrast, p53 strongly 
accumulated in the nuclei of stimulated p53-wt cells (Figure 2e). 
Not only low levels of endogenous TAp73 can explain the miss-
ing prMinRGC-activation in p53-dysfunctional cells, but also 
a neutralizing balance of p73 isoforms could be responsible for 
low promoter activation. The p73-gene also encodes isoforms 
(ΔNp73) that lack a transactivation domain and can nega-
tively interfere with p53- and TAp73-dependent transcription. 
Therefore, we tried to shift the balance between endogenous p73 
isoforms by an siRNA approach and investigated prMinRGC-
promoter activation. For knockdown of all isoforms, siRNA 
was directed against the DNA-binding domain (DBD) of p73. 
siRNA against the transcription activation domain was applied 
to selectively interfere with transcriptionally activating iso-
forms (Figure 3a). In p53-wt cells, a p73-knockdown did not 
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Figure 2 the prMinrGc promoter responds to p53 with a high signal/noise ratio and is not activated by endogenous levels of other p53 
family members in tumor cells after adenoviral infection or chemotherapy. (a) Hep3B cells were co-transfected with 1 µg prMinRGC-Luc or 
prMinCon-Luc, 0.3 µg CMV-LacZ, and 0.05 µg expression plasmid for p53 family members (pC53SN3, TAp63α, pcDNA3-HA-p73α, or pcDNA3-HA-
p73β). Thirty-six hours after transfection, luciferase activity was determined. (b) Cells were transfected with 1 µg prMinRGC-Luc and 0.3 µg CMV-βgal 
to investigate reporter activation by endogenous p53 or p53-homologues. Doxorubicin was administered at a final concentration of 200 ng/ml. The 
reporter-free background level is illustrated by the dotted line. (c) Enumerates the known genetic p53/p73 status of the used cell lines. (d) SAOS-2 
and H1299 cells were stimulated with doxorubicin (200 ng/ml) and/or Ad-LacZ at multiplicity of infection of 25. Nuclear extracts were analyzed for 
p73α and p73β. (e) Nuclear extracts of p53-positive A549 and HepG2 after similar treatment were analyzed for p53.
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interfere with p53-dependent induction of prMinRGC-activity 
 suggesting that fully activated p53 dominates the transcriptional 
activation (Figure 3b). In p53-negative H1299 cells, we observed 
a reduced reporter activity after selective knockdown of acti-
vating isoforms, but increased activity after silencing all p73 
isoforms suggesting that the simultaneous presence of TAp73 
and ΔNp73 isoforms results in a net inhibition of the promoter 
(Figure 3c). We then investigated whether a p73-knockdown is 
able to  modulate p53-dependent transcription under conditions 
of attenuated p53-activity in p53-wt cells (Figure 3d). siRNA-
mediated reduction of the p53-response by p53-directed siRNA 
and simultaneous silencing of all p73 isoforms reconstituted 
prMinRGC-activation to 20% of the full activity, a level that 
could not be reached by silencing of Mdm2, the physiological 
inhibitor of p53. These data suggest that endogenous p73 is able 
to efficiently interfere with attenuated p53-dependent transcrip-
tion for the purpose of fine-tuning the transcriptional response. 
However, the data show that p73 is neither able to interfere with 
a fully developed p53-transcriptional response nor capable to 
significantly induce prMinRGC promoter activity under condi-
tions of p53-dysfunction.
Adp53sensor replicates in a p53-dependent,  
but p73-independent manner
To investigate p53-dependent regulation of adenoviral replica-
tion, we used Adp53sensor in comparison to AdCtrl, a geneti-
cally similar, but p53-nonresponding control virus that lacks the 
prMinRGC-promoter. Consequently, the contribution of p53 or 
p53-analogous activity to conditioned replication and lysis can 
be directly determined by comparison of these two viruses in 
any given cell line. At first, we investigated E1A expression after 
viral infection of cell lines with different p53 status (Figure 4a). 
Consistent with our hypothesis, p53-dysfunctional cells expressed 
similar levels of E1A after infection with Adp53sensor or AdCtrl, 
and Gal4-KRAB expression could not be observed. In contrast, 
Gal4-KRAB was expressed after infection of p53-wt cells with 
Adp53sensor, that was further triggered by increasing doses of 
doxorubicin. The inverse correlation between E1A and Gal4-
KRAB levels not only indicates the correct function of the p53-
dependent control loop in Adp53sensor, but also underlines the 
usefulness of chemotherapy for additional triggering.
To investigate whether Adp53sensor replication and cytol-
ysis is selectively inhibited in the presence of active p53, we 
examined the morphology of cells with different p53 status fol-
lowing infection (Figure 4b). Doxorubicin-pretreated HepG2 
cells retained intact morphology 5 days after Adp53sensor infec-
tion, whereas AdCtrl-infected cells showed a strong cytopathic 
effect. Because both vectors effectively lysed p53-mutant cells, 
these observations suggest that Adp53sensor indeed functions 
as a p53-dependent oncolytic virus. Titration of the viral prog-
eny (Figure 4c) revealed significantly reduced Adp53sensor 
titers in HepG2 cells compared to AdCtrl, showing that differ-
ential cytolysis correlated with the inhibition of viral replica-
tion. These data suggest that p53-dependent silencing of E1A 
expression inhibits adenoviral replication and lysis of infected 
cells. Investigation of viral replication in additional cell lines 
confirmed that Adp53sensor was selectively attenuated in p53-
active cells and that attenuation was significantly increased 
by doxorubicin (Figure 4c). Adp53sensor produced signifi-
cantly less viral particles in p53-normal cells than Onyx-015. 
This finding was independent of chemotherapy application. 
Because Adp53sensor and AdCtrl replicated equivalently in all 
p53-dysfunctional cells, we could not find any correlation to 
the cellular p73-status. In general, Adp53sensor showed sig-
nificantly improved replication compared to Onyx-015 in most 
p53-dysfunctional cells. Equivalent replication of both vectors 
could only be observed in Hep3B cells. This can be explained 
by expression of the HBV-derived transactivator protein HBx in 
Hep3B cells that has been reported to support adenoviral replica-
tion.23 Taken together, our results demonstrate that Adp53sensor 
is selectively attenuated in response to activated p53 but is able 
to efficiently replicate in p53-dysfunctional cells in vitro. To 
further confirm these findings in vivo, conditional replication 
of Adp53sensor was investigated in a subcutaneously grown, 
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p53-positive A549 xenograft model (Figure 4d). Tumor-bearing 
mice were treated with doxorubicin and intratumorally infected 
with Adp53sensor, AdCtrl, or Ad-LacZ (a replication-defective 
virus). In this model, treatment with Adp53sensor seemed to 
inhibit the growth of A549 tumors more efficiently compared 
to the replication-incompetent Ad-LacZ (no statistic signifi-
cance). However, consistent with the p53-selective attenuation 
of Adp53sensor, we found that Adp53sensor lysed A549 tumors 
less efficiently compared to AdCtrl. Though the measured differ-
ence was statistically significant, the effect was rather moderate. 
It has to be considered in this model that intratumoral infections 
usually lead to superinfection of tumor tissue surrounding the 
point of injection. Superinfection with high multiplicity of infec-
tions of conditionally replicating adenoviruses may result in a 
loss of selectivity. In a subcutaneous model of p53-dysfunctional 
Huh7 tumors, Adp53sensor and AdCtrl showed a comparable 
lytic activity (data not shown).
Adp53sensor is highly attenuated in primary 
hepatocytes in vitro and in vivo
Tumor cell lines most likely do not reflect the p53-response of 
normal cells, and active cell cycling can additionally provide a 
favorable environment for adenoviral replication. Therefore, 
investigations in these cells may lead to underestimation of the 
p53-selectivity of Adp53sensor. To address this point in a physi-
ologically more relevant setting, we infected primary human 
hepatocytes (Figure 5a). Determination of intracellular viral 
titers revealed a strong inhibition of Adp53sensor replication 
compared to AdCtrl that was further supported by doxorubicin. 
Although replication of Onyx-015 was only reduced compared 
to Ad-wt, Adp53sensor was almost incapable of replication. 
Interestingly, AdCtrl replication was also significantly reduced 
compared to the Ad-wt suggesting a constitutionally defective 
replication of the AdCtrl/Adp53sensor strategy in hepatocytes. 
This observation might be explained by a delayed activation 
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Figure 4 Adp53sensor replication is selectively attenuated in p53-normal cells. (a) Cell lines harboring transcriptionally active p53 (HepG2, 
HT1080, A549, and MCF-7) or p53-transcriptionally dysfunctional cells (Hep3B, HeLa, Huh7, SAOS, and H1299) were treated with variable doses of 
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of the CMV-promoter after viral cell entry in hepatocytes. The 
CMV-promoter used to control E1A expression in AdCtrl/
Adp53sensor is known to be constitutionally active in tumor cell 
lines and is also more active compared to the E1A-promoter in 
transient transfection assays (Figure 1f). In contrast, it has been 
shown that the CMV-promoter is inactive in resting liver cells 
and can be reactivated by cellular stress via NFκB-dependent 
pathways.24 Therefore, activation of the CMV-promoter is most 
likely influenced by the mode of infection that differs between 
low multiplicity of infection application in vitro and intrave-
nous injection in vivo. It can also not be excluded that the use 
of the CMV-promoter contributes to the tumor selectivity of 
Adp53sensor by delayed E1A expression in resting, normal 
cells.
p53-selective regulation of Adp53sensor was finally addressed 
in an isogenic setup in vivo. For this purpose, we infected the 
livers of normal and p53-knockout mice by intravenous admin-
istration and determined the intrahepatic load of viral DNA. 
Though primary murine cells are unable to assemble infectious 
virions of human adenovirus, the viral genome is normally ampli-
fied. To allow proper dissection of virus uptake from replication, 
the replication-incompetent Ad-LacZ was applied as standard 
(Figure 5b). Compared to AdCtrl, Adp53sensor DNA load was 
significantly reduced after infection of p53-normal mice. In con-
trast, both viruses replicated to the same extent in p53-knockout 
mice confirming that the control of Adp53sensor replication 
depends on p53. Though replication of Adp53sensor was not 
completely inhibited in this experimental setup, selectivity was 
significantly improved compared to Onyx-015.
The pulsed entry of high particle doses into the liver following 
intravenous injections results in overinfection of the periphery 
of liver portal fields that may circumvent the selectivity of con-
ditionally replicating adenoviruses. We therefore investigated the 
hepatic load of adenoviral DNA in a murine model that provides 
a steady release of infectious particles into the blood flow that 
can be expected during virotherapeutic treatments (Figure 5c). 
Because murine cells do not produce infectious progeny, the con-
sequences of virus release by infected liver cells and subsequent 
infection of neighboring cells in the human system cannot be 
taken into account. For our investigations, we injected preinfected 
Hep3B cells into the tail vein of mice. Hep3B cells were selected 
because they provide a comparable replication of the investigated 
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Figure 5 Adp53sensor replication is selectively inhibited in primary human hepatocytes in vitro and in mouse livers in vivo. (a) Primary 
human hepatocytes were treated with 200 ng/ml doxorubicin (right panel) or left untreated (left panel). After 8 hours, cells were infected with 
a replication-defective virus (Ad-GFP), Adp53sensor, AdCtrl, Onyx-015, or Ad-wt at an MOI of 0.005. At the time points indicated, intracellular 
viral titers were determined. The data show that Adp53sensor replication is almost completely inhibited in primary human hepatocytes. (b) p53-
selectivity of Adp53sensor replication was investigated in vivo by comparison of viral DNA replication in normal mice and p53-knockout mice 
after intravenous infection. p53-normal (left) or p53-knockout mice (right) were injected intravenously with 1 × 107 infectious particles. At the 
indicated time points, DNA was prepared from liver tissue, and the content of viral DNA was determined by qPCR. In normal mice, replication 
of Adp53sensor was significantly inhibited compared to AdCtrl. Because both viruses replicated comparably in p53-knockout mice, these results 
confirm in vivo that attenuation of Adp53sensor replication is dependent on p53. (c) For analysis of intrahepatic viral load in a virotherapeutic 
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infection. *P < 0.05, **P < 0.005.
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oncolytic viruses (see Figure 4c). After systemic release of AdCtrl 
and Onyx-015, we could observe a significantly increasing liver 
load of adenoviral DNA. In contrast, Adp53sensor DNA levels 
were almost similar compared to a replication-defective vector 
confirming the tight control of Adp53sensor replication under 
physiologic conditions of a virotherapeutic simulation.
Adp53sensor shows efficient oncolytic properties 
and demonstrates improved lytic efficacy 
compared to onyx-015
The oncolytic potency as a critical therapeutic parameter was 
investigated in a panel of tumor cells (Figure 6). In line with 
the replication data described above, Adp53sensor showed 
significantly enhanced p53-selectivity compared to Onyx-015, 
which was further improved by chemotherapeutic triggering. 
Adp53sensor-mediated oncolysis of p53-dysfunctional cells 
was generally stronger compared to Onyx-015. The oncolytic 
potency of Adp53sensor was further confirmed by the observa-
tion that the extent of cytolysis was almost as efficient as Ad-wt-
mediated cytolysis. Irrespective of the p73-status, Adp53sensor 
showed the same capacity of oncolysis as AdCtrl in all p53-
dysfunctional cells that were investigated, which is consistent 
with the inability of p73 to transactivate the p53-dependent 
promoter prMinRGC after viral infection and chemotherapy as 
shown above.
combined Adp53sensor and chemotherapy 
application inhibits tumor growth in vivo
To address therapeutic applicability of Adp53sensor in vivo, 
we investigated oncolytic efficacy in xenotransplant models. 
As shown in Figure 7a,b, application of Onyx-015 resulted in 
a growth delay in both xenograft models, whereas doxorubicin 
hardly reduced the tumor growth. However, doxorubicin sig-
nificantly improved the efficacy of both virotherapeutic vectors. 
p53-daysfunction p53-wt
H1299
A673
Huh7
HeLa
Saos
SW872
Hep3B
Legend:
La
cZ
p5
3s
en
so
r
Ctr
l
On
yx
Wt un
tr.Ad():
MOI
5
0.5
0.05
0.005
HT1080
MCF-7
A549
HepG2
− Doxo + Doxo − Doxo + Doxo
Figure 6 Adp53sensor shows improved p53-selectivity and onco-
lytic properties in vitro compared to onyx-015. p53-selectivity of 
Adp53sensor and lytic potency in p53-inactive tumor cells was analyzed 
in oncolysis assays. Cells were treated with or without doxorubicin as 
described in the Materials and Methods section and infected 8 hours later 
at the indicated MOI. After 5–6 days of incubation, the cell layer destruc-
tion was visualized by crystal violet staining. The results demonstrate 
that Adp53sensor lysed p53-deficient cells more efficiently compared 
to Onyx-015. Selectivity of Adp53sensor replication and Adp53sensor-
mediated cell lysis was significantly increased after chemotherapeutic 
triggering. MOI, multiplicity of infection.
Ad-GFP
Ad-wt
Adp53
sensor
Onyx
Doxo
Ad-wt
+ Doxo
1 mm
Adp53
sensor
+ Doxo
Onyx
+ Doxo
Ad-GFP10
8
6
4
2
5 10 15 20 25
R
el
at
ive
 tu
m
or
 s
ize
 (x
-fo
ld
)
10
8
6
4
2
R
el
at
ive
 tu
m
or
 s
ize
 (x
-fo
ld
)
Doxo
Onyx
Ad-wt
Ad-wt + Doxo
Onyx + Doxo
Adp53sensor
Adp53sensor + Doxo
Ad-GFP
Doxo
Onyx
Ad-wt
Ad-wt + Doxo
Onyx + Doxo
Adp53sensor
Adp53sensor + Doxo
Hep3B
Huh7
‡ = aborted
5 10
Days after initial injection
15 20 25
a
b
c
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Particularly in Huh7 xenografts, Adp53sensor inhibited tumor 
growth more efficiently compared to Onyx-015, and was as 
efficient as the Onyx-015/chemotherapy combination. In the 
Hep3B-model, the difference between Adp53sensor and Onyx-
015 was not significant, an observation that could also be due to 
the HBx expression of Hep3B cells as mentioned above. Finally, 
the maximum therapeutic effect in both models was achieved 
after combined treatment with chemotherapy and Adp53sensor, 
or Ad-wt, respectively. A therapeutic advantage of Ad-wt com-
pared to Adp53sensor could only be observed without chemo-
therapy. Systemic administration of Adp53sensor or wild type 
did not result in a significant therapeutic benefit due to relatively 
poor tumor transduction (data not shown).
Ineffective removal of dead cells and replacement by fibrotic 
tissue can lead to underestimation of the true therapeutic 
efficacy when tumor growth curves are studied. Therefore, 
HE-stained sections were performed from tumor xenografts 
after defined treatments. Following Onyx-015 treatment, 
tumors revealed a speckled pattern of necrotic and vital sub-
zones (Figure 7c). Significantly increased tissue destruction 
and larger fields of advanced necrosis could be observed after 
treatment with Adp53sensor alone or after Onyx-015/chemo-
therapy combination. In contrast, tumor nodules that remained 
after chemotherapy/Adp53sensor virotherapy predominantly 
consisted of scar tissue containing loosely dispersed cells of 
fibrotic morphology.
p53-selective attenuation of Adp53sensor results in 
reduced liver damage
During virotherapy, a significant proportion of the released 
adenoviral progeny can be flushed out of the tumor bed thereby 
threatening the liver as the predominant target organ of systemic 
adenoviral infections. Tight replication control of oncolytic aden-
oviruses is therefore an important prerequisite for the protection 
of the liver. To address the question of hepatic toxicity directly, 
doxorubicin-pretreated mice were intravenously infected. After 3 
days, blood samples were drawn and serum transaminase activities 
were determined (Figure 8a). Explanted livers were investigated 
for macroscopic signs of liver damage (Figure 8b). Livers from 
mice that received only doxorubicin or Ad-LacZ/doxorubicin 
were undistinguishable from untreated livers. Though ALT/AST 
levels were moderately elevated after infection with Adp53sensor 
compared to doxorubicin alone or Ad-LacZ, no significant liver 
damage was macroscopically detectable. In contrast, a severe liver 
damage and a dramatic increase of serum transaminase activ-
ity could be observed after infection by AdCtrl. Together, our 
results confirm antitumoral efficacy of Adp53sensor and indi-
cate an improved protection against systemic side effects during 
Adp53sensor virotherapy.
dIscussIon
Inhibition of p53-transcriptional activity represents a hallmark 
of almost all cancers. Consequently, a strategy that restricts viral 
replication to cells with p53-transcriptional dysfunction would 
provide means for constructing oncolytic vectors for the major-
ity of human cancers. Some concepts have already been devel-
oped for targeting of p53-alterations by viruses. Most prominent 
in this regard are Onyx-015 and existing variants. However, p53-
 specificity of Onyx-015 has been questioned by several groups,25–28 
and other studies suggested that E1B-55k-mediated degradation 
of p53 is not necessary to allow for adenoviral replication.29,30 In 
another study, the adenovirus 01/PEME has been presented that 
targets both p53-dysfunctional and E2F-active tumors.31 Though 
01/PEME-replication was attenuated in primary human fibroblasts, 
replication was not inhibited in A549 and HepG2 cells, despite 
transcriptionally active p53. In contrast, we demonstrate that repli-
cation of Adp53sensor was significantly inhibited in these cell lines 
thus confirming the stringency of p53-dependent E1A repression. 
In 01/PEME, p53-dependent inhibition of viral replication was 
only achieved when an N-terminally variant of E1A was used that 
reduces negative interference with p53- dependent transactivation. 
Our data suggest that the E1A silencing by  targeted repression used 
for Adp53sensor is sufficient to avoid negative interference of viral 
proteins with p53-transcriptional activity and thus allowed appli-
cation of wild-type viral genes for an unaltered course of the viral 
life cycle. In contrast to Onyx-015 and 01/PEME, we could show 
that the p53-specificity of Adp53sensor solely relies on the pres-
ence of p53-dependent transcription in target cells. Addressing 
the safety of Adp53sensor application, we further demonstrated 
that Adp53sensor led to reduced viral load in mice livers during 
virotherapeutic simulations and that mice were protected from 
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Figure 8 After high-dose intravenous delivery, application of 
Adp53sensor leads to reduced liver damage in mice. Mice were 
pretreated with doxorubicin (1.75 µg/g body weight) 6 hours prior to 
systemic adenovirus application. Then, 3 × 108 infectious particles of 
Adp53sensor, AdCtrl, or Ad-LacZ (replication-defective control) were 
intravenously delivered. (a) Seventy-two hours following infection, mice 
were harvested, blood samples were drawn, and transaminase activity 
was determined in the serum. (b) Livers were explanted and macro-
scopically examined to estimate the extent of liver damage. Our results 
demonstrate that attenuated replication of Adp53sensor compared to 
AdCtrl protected the mice from severe liver damage. **P < 0.005.
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severe liver damage following  administration of high  systemic 
adenovirus doses. A central question for the applicability of onco-
lytic viruses targeting p53-transcriptional deficiency is the role of 
other p53 family members that can potentially compensate for 
the lack of p53-transcriptional functions. In contrast to p53, the 
p53- homologues, p73 and p63, are rarely mutated in tumors.32 
However, as recently confirmed by studies carried out in TAp73 
knockout mice, only the transactivating isoforms can be classified 
as tumor suppressors.33 Although p53 primarily acts as a tumor 
suppressor in stress response pathways, mice with complete p73- 
or p63-knockout have shown that these proteins preferably play 
an important role in differentiation and embryonal development 
than in protection against cancer.34–36 On the other hand, studies 
have revealed that mutant p53 or ΔNp63 can interact and down-
regulate the function of p73, providing a molecular explanation for 
the gain of function of p53-mutations and suggesting a role of p73 
and p63 in carcinogenesis.37–40 Several groups have reported that 
p73 and p63 are induced by cisplatin or doxorubicin.15,16,19,38,39,41 
Additionally, inactivation of p73 and p63 confers p53-indepen-
dent chemoresistance, at least in part due to the lack of p73- and 
p63-mediated transactivation of proapoptotic genes like AIP1, 
BAX, CD95, and PUMA.14 The prMinRGC- promoter used in 
Adp53sensor showed a comparable susceptibility for transacti-
vation by p73β or p53, when these proteins were overexpressed. 
Regarding the endogenous situation, nuclear p73β-levels following 
adenoviral infection or chemotherapy appeared to be insufficient 
to trigger a transcriptional response like p53. A p73-knockdown 
in p53-deficient cells rather suggested an inhibitory function of 
endogenous p73 on the p53-responsive promoter used in this 
study. Consistent with the inability of endogenous p73 to activate 
the prMinRGC-promoter after stimulation, the oncolytic efficacy 
of Adp53sensor was not compromised in any of the investigated 
p53-dysfunctional cells, regardless of the cellular p73-status. Our 
results therefore indicate that p53-transcriptional dysfunction is 
a well-suited, broad-range target for therapy of HCC and is not 
restricted by other p53 family members. Finally, a general advan-
tage of the Adp53sensor strategy is the applicability for the design 
of further oncolytic viruses because it should be transferable to 
other DNA viruses such as CMV or HSV. Thus, the strategy imple-
mented in Adp53sensor could provide a general method for engi-
neering a broad spectrum of p53-dependent oncolytic viruses for 
the treatment of p53- dysfunctional tumors.
MAterIAls And Methods
Cells. Human Hep3B, HepG2, HT1080, A549, H1299, SAOS-2, MCF-7, 
HeLa, and 293 cells were obtained from ATCC (Rockville, MD). Huh7 
cells were obtained from the JCRB (Osaka, Japan). A673 and SW872 were 
provided by the CNIO (Madrid, Spain). Human primary adult hepatocytes 
were purchased from Cytonet (Hannover, Germany).
Adenoviruses and plasmids. The plasmids pcDNA3-HA-p73α and 
pcDNA3-HA-p73β were kindly provided by W.G. Kaelin. The plasmids 
pC53SN3 and pSK-45-13-2-PyCAT were kind gifts by B. Vogelstein. The 
plasmid pZIKΔBH was kindly provided by L. Lania. pAdApt was kindly 
given by R. Hoeben.
The vectors prMinRGC-GAL4KRAB, prMinRGC-Luc, prMinCon-
Luc, and CMVgal-Luc have been described previously.
12
For construction of the plasmid prE1A-Luc, the Ad5-E1A-promoter 
(pos. 2–558) was PCR-amplified from adenoviral DNA (primers: 5′-CC
GAGCTCATCAATAATATACCTTATTTTGGATTGAAGCC-3′ and 5′-
GTAAGCTTCAGTCCCGGTGTCGGAGCGG-3′) and cloned into pGL2-
Basic (Promega, Mannheim, Germany).
The bicistronic adenoviral vectors Adp53sensor and AdCtrl were 
constructed on the basis of the shuttle plasmid pHM3 containing a 3′-
CMVgal/E1/IRES/EGFP/pA followed by a 5′-prMinRGC-GAL4KRAB/pA 
expression unit (cloning details upon request). For the generation of the 
p53-independent replicating AdCtrl, a promoterless Gal4-KRAB-cassette 
was used. pHM3-CMVgal/E1/IRES/EGFP/pA/(prMinRGC)-GAL4KRAB/
pA constructs were released from the plasmid backbone by digesting 
PI-Sce and I-CeuI, and recombinant adenoviruses were constructed 
according to a ligation method described previously.42 This construction 
finally yielded adenoviruses of an approximate length of 36.8 kilobases 
(kb) (Adp53sensor) and 36.3 kb (AdCtrl). Viruses were propagated in 
293 cells according to standard procedures. In general, significantly 
lower yields were obtained compared to standard adenoviruses such as 
Ad-wt. Because preparations were checked by PCR for eventual loss of 
heterologous DNA fragments and for the length of repetitive sequences, 
we could not find significant evidence for genetic instability or formation 
of shortened, deregulated viruses.
Luciferase assays. 6 × 105 cells were seeded in 60 mm dishes the day before 
transfection. Cells were transfected using the calcium phosphate precipita-
tion method or Lipofectamine (Invitrogen, Carlsbad, CA). Generally, 1 µg 
luciferase reporter plasmid (prMinRGC-Luc, prMinCon-Luc, prE1A-Luc) 
and 0.3 µg pCMV-LacZ for normalization were adjusted with pBluescript 
KS (Stratagene, La Jolla, CA) to 5 µg DNA per dish. Chemotherapeutic/
adenovirus treatment was performed as described in the figure legends. 
Forty-eight hours after transfection, extracts were obtained according to 
standard protocols, luciferase activity was determined, and luciferase mea-
surements were normalized by β-galactosidase assay.
RNA interference. siRNA-mediated knockdown of p73 was evaluated by 
real-time quantitative PCR. 5 × 105 H1299 cells were transfected twice 
with 40 pmol siRNA using HiPerfect (Qiagen, Hilden, Germany). Twenty-
four hours after transfection, doxorubicin was added (200 ng/ ml). After 
48 hours, total RNA was extracted using peqGOLD-RNAPure (PeqLab, 
Erlangen, Germany). Reverse transcription was performed using the 
TaqMan-Kit (random hexamer as primer; Applied Biosystems, Foster 
City, CA) followed by DNase-digestion. cDNA was subjected to quantita-
tive PCR using SYBR Green in an ABI 7300 cycler (Applied Biosystems). 
Quantitative PCR for determination of total p73 was performed using 
primers against the DBD (5′-GTGACCGACGTCGTGAAACGCTGC-3′ 
and 5′-CTGGCTGGAGCAGACTGTCCTTCG-3′). Transactivating p73 
isoforms were quantified using primers against the transcriptional activa-
tion domain (5′-CAGACAGCACCTACTTCGACCTTCC-3′ and 5′-GGA
AGACGTCCATGCTGGAATCCG-3′). Ct-values were normalized against 
GAPDH. Used siRNAs against all p73 isoforms were directed against the 
sequences 5′-CTCGGGAGGGACTTCAACGAA-3′ (“DBD”). siRNA 
against transactivating p73 isoforms was described previously.43 The p53-
siRNA, MDM2-siRNA, and the “negative control siRNA” were purchased 
from Qiagen. For siRNA-mediated knockdown, co-transfection assays 
with prMinRGC-Luc as reporter and CMV-LacZ as internal control were 
performed using Lipofectamine 2000 (Invitrogen).
Western blot analysis. Whole cell extracts were prepared using radio-
immunoprecipitation assay buffer according to standard protocols. For 
nuclear extract preparation, the cell pellet was resuspended in 200 µl NPB 
(10 mmol/l TrisCl pH 7.4, 2 mmol/l MgCl2, 140 mmol/l NaCl) supple-
mented with 0.1% Triton-X100. The nuclei were centrifuged through a 
50% sucrose cushion in NPB (10 minutes, 4 °C, 15,000 g). The supernatant 
was removed and nuclei were lysed with radioimmunoprecipitation assay. 
Ten micrograms of protein (for detection of p73: 100 µg) were separated on 
a 10% SDS gel and blotted onto a HyBond membrane (Millipore, Billerica, 
MA). Loading was controlled by Ponceau-Red staining (nuclear fractions) 
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and  β-actin-blot (whole cell extracts). Used primary antibodies were as 
 follows: anti-p53 Ab-6 (Calbiochem, Nottingham, UK); anti-p73 antibody 
(BL906; Bethyl Laboratories, Montgomery, TX); and anti-Gal4-DBD and 
anti-Ad2 E1A (Santa Cruz, Santa Cruz, CA). Bands were visualized using 
ECL (Amersham, Freiburg, Germany).
Quantitative analysis of viral titers. For measurement of viral replica-
tion kinetics, 0.5–1 × 106 cells were plated and grown to subconfluency. 
On the day of infection, the medium was exchanged by medium con-
taining 2% fetal bovine serum ± doxorubicin. After 8 hours, cells were 
adenovirally infected. At the time points indicated in the figures, cells 
were harvested in 0.5 ml phosphate-buffered saline, viral particles were 
released by repeated freezing/thawing and titered by rapid titer assay (BD 
Biosciences, San Jose, CA).
Oncolysis assays. Depending on cell size and proliferation speed, cells were 
seeded in 24-well plates at a density of 0.5 × 104 to 2.5 × 105 per well and 
grown for subconfluency at the time of infection. Doxorubicin was then 
applied at concentrations that allow cell survival for ~1 week: 200 ng/ ml 
(HepG2, A549); 150 ng/ml (MCF-7, Huh7); 100 ng/ml (U2-OS, H1299, 
SW872, HeLa, Hep3B, HT1080); and 50 ng/ml (SAOS-2, A673). After 
8 hours, adenovirus was added. After 5–6 days, cell layer destruction was 
visualized by crystal violet staining.
Animal experiments. Six-week-old, homozygous p53-knockout mice 
(inbred from strain B6.129S2-Trp53tm1Tyi/J; Jackson Laboratory, Bar Harbor, 
ME) were provided by the Central Animal Facility at the Helmholtz Centre 
of Infection Research (HZI, Braunschweig, Germany). Six-week-old 
C57BL/6 and NMRI nu/nu mice were obtained from the Animal Research 
Institute of the Hannover Medical School. All animal experiments were 
performed according to the German legal requirements. To examine the 
therapeutic efficacy, tumor xenografts were established by subcutane-
ous injection of 1 × 107 cells (Hep3B, H1299) into both flanks of mice. 
Tumor nodules were grown to a size of ~250 mm3. As chemotherapy, mice 
received i.v. injections of 1.75 µg doxorubicin/g body weight once a week. 
Intratumoral treatments with adenovirus were performed on days 0, 7, 
14, and 21 by injection of 1 × 109 infection forming units. For statistical 
tumor growth assessment, infected tumors were measured twice a week. 
Tumor volume was calculated using the equation: V(tumor) = (length 
× width2)/2. For each group, six tumors were assessed. At the end of the 
experiment, paraffin sections of the tumors were stained by hematoxylin/
eosin. Microscopic images were made at 40-fold magnification with a Zeiss 
Axiom-mcR camera (Carl Zeiss, Jena, Germany) and  processed using 
AxioVision software (Carl Zeiss).
To determine Adp53sensor selectivity in a tumor model in vivo, nude 
mice were subcutaneously inoculated with 1 × 107 A549 cells, and tumors 
were grown to a size of ~200 mm3. Tumors were infected and treated with 
doxorubicin as described in the figure legend.
Determination of intrahepatic viral load and liver damage. For analy-
sis of intrahepatic viral DNA following systemic adenoviral infection, 
mice were pretreated intravenously with doxorubicin (1.75 µg/g body-
weight), 6 hours prior to adenovirus injection. For the analysis of intra-
hepatic viral DNA during a virotherapeutic simulation, Hep3B cells were 
infected at multiplicity of infection of 25 (almost complete infection). 
After 24 hours, 5 × 105 cells were injected i.v. in doxorubicin-pretreated 
mice (performed as described above). At the time points indicated in 
the figures, mice were killed, and DNA from liver tissue was purified 
using the QIAmp-DNA-Mini Kit (Qiagen). Viral DNA quantification 
was performed by real-time PCR (qPCR MasterMix Plus; Eurogentec, 
Seraing, Belgium) using 100 ng of liver DNA and adenoviral hexon-
specific primer probes as described before.44 18S Genomic Control Kit 
(Eurogentec) served as internal control. For the investigation of liver 
damage, explanted livers were examined macroscopically, and ALT/AST 
activities were determined in serum samples from treated mice using 
the AST/ALT enzymatic assay kit (Bioo Scientific) according to the 
manufacturer’s protocols.
Statistics. Two groups were compared by unpaired t-test. P < 0.05 was 
 considered as statistically significant.
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